Cleerly, a pioneering company dedicated to eradicating heart attacks, has successfully raised an impressive $106 million in its latest funding round. This significant investment will bolster Cleerly's mission of redefining the standard of care in heart disease diagnosis through its innovative, AI-powered solutions. By focusing on comprehensive phenotyping of coronary artery disease, Cleerly utilizes advanced non-invasive CT imaging to assess and stratify risk in patients more accurately than ever before. This funding will not only accelerate their research and development efforts but also enhance their ability to scale operations and improve health literacy for all stakeholders involved in the coronary care pathway. With nearly 20 years of scientific validation from landmark multi-center clinical trials, Cleerly stands at the forefront of transforming cardiac healthcare. This latest influx of capital will enable the company to further refine its cutting-edge technologies, expand its reach into new markets, and significantly contribute to the fight against a leading cause of death worldwide. As the healthcare landscape continues to evolve, Cleerly remains committed to delivering transformative solutions that empower patients and healthcare providers alike, ensuring that every individual has access to the best possible care in preventing heart disease. With this funding, Cleerly is poised to make significant strides towards its vision, promising a future where heart attacks are a thing of the past.













